MSACL 2019 US Abstract

Apolipoprotein L1 is Associated with Larger HDL Particles in CKD

Andy Hoofnagle (1), Michael Andrews (2), Zsuzsanna Kuklenyik (2), Ian de Boer (1), Bryan Kestenbaum (1)
(1) University of Washington, Seattle, WA (2) Centers for Disease Control and Prevention, Atlanta, GA

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Andy Hoofangle (Presenter) Unversity of Washington

Presenter Bio: Andy Hoofnagle is Professor of Laboratory Medicine, Head of the Division of Clinical Chemistry, and Director of Reference Laboratory Services in the Department of Laboratory Medicine, University of Washington, Seattle. His laboratory focuses on developing novel methods for the quantification of proteins and small molecules in clinical samples using LC-MS/MS. His grant-funded research continues to focus on using analytical chemistry to epidemiologically answer questions in vitamin D biology, cardiovascular disease, and cancer. Professor Hoofnagle mentors students, fellows, and residents in gaining a deeply respectful admiration for the power of mass spectrometry in the care of patients.

Relevant Financial Disclosures (within past 24 months) Grant/Research Support Waters, Inc. Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED.

Patients with chronic kidney disease (CKD) are at greatly increased risk of cardiovascular disease. High density lipoproteins (HDL) may help prevent the development of atherosclerosis. We hypothesized that CKD leads to alteration of HDL proteins and HDL dysfunction. Using targeted proteomics, we determined that Apolipoprotein L1 (ApoL1) was significantly reduced in the HDL fraction of serum in patients with CKD. However in plasma, targeted proteomics demonstrated that ApoL1 is not correlated with estimated glomerular filtration rate (eGFR). To determine where in plasma ApoL1 resides in patients with CKD, we used asymmetric flow field flow fraction (AF4) and targeted proteomics and found that ApoL1 resides in larger particles in CKD. We also used LC-MS/MS to demonstrate that ApoL1 in urine correlates with eGFR, suggesting a role for plasma and urine ApoL1 in the development of CKD.